-
公开(公告)号：US10245267B2
公开(公告)日：2019-04-02
申请号：US15601423
申请日：2017-05-22
Applicant: NOVARTIS AG
Inventor： Robert John Aversa , Paul Andrew Barsanti , Matthew T. Burger , Michael Patrick Dillon , Alan Dipesa , Cheng Hu , Yan Lou , Gisele A. Nishiguchi , Yue Pan , Valery Rostislavovich Polyakov , Savithri Ramurthy , Alice C. Rico , Lina Quattrocchio Setti , Aaron Smith , Sharadha Subramanian , Benjamin R. Taft , Huw Roland Tanner , Lifeng Wan , Naeem Yusuff
IPC: C07D295/04 , A61K31/5377 , C07D413/04 , A61K31/541 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D403/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D493/10 , C07D403/12 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D401/04 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D491/048 , A61K31/444 , A61K31/501 , C07B59/00 , C07D237/24 , C07D491/04 , C07D491/08
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US10377770B2
公开(公告)日：2019-08-13
申请号：US16062680
申请日：2016-12-15
Applicant: Novartis AG
Inventor： Robert John Aversa , Matthew T. Burger , Michael Patrick Dillon , Thomas A. Dineen, Jr. , Rajesh Karki , Savithri Ramurthy , Vivek Rauniyar , Richard Robinson , Patrick James Sarver
IPC: C07D487/04 , C07D491/04 , C07D498/04 , A61P35/00 , C07D491/044
Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.
-
Patent Agency Ranking
公开(公告)号：US10167279B2
公开(公告)日：2019-01-01
申请号：US15510609
申请日：2015-09-11
Applicant: NOVARTIS AG
Inventor： Robert John Aversa , Matthew T. Burger , Michael Patrick Dillon , Thomas A. Dineen, Jr. , Yan Lou , Gisele A. Nishiguchi , Savithri Ramurthy , Alice C. Rico , Vivek Rauniyar , Martin Sendzik , Sharadha Subramanian , Lina Quattrocchio Setti , Benjamin R. Taft , Huw Rowland Tanner , Lifeng Wan
IPC: C07D405/14 , C07D405/12 , C07D305/06 , A61P35/00 , C07D413/14
Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US10947218B2
公开(公告)日：2021-03-16
申请号：US16884666
申请日：2020-05-27
Applicant: NOVARTIS AG
Inventor： Luca Arista , Sreehari Babu , Jianwei Bian , Kai Cui , Michael Patrick Dillon , Rene Lattmann , Jialiang Li , Lv Liao , Dimitrios Lizos , Rita Ramos , Nikolaus Johannes Stiefl , Thomas Ullrich , Peggy Usselmann , Xiaoyang Wang , Liladhar Murlidhar Waykole , Sven Weiler , Yubo Zhang , Yizong Zhou , Tingying Zhu
IPC: A61K31/4427 , C07D405/14 , C07D401/14 , C07D401/10 , C07D401/12 , C07D409/14 , C07D213/82 , C07D411/14 , C07D491/107 , A61P19/00 , C07D417/00 , C07D413/00 , C07D419/00 , A61P19/08 , C07D413/10 , C07D413/12 , C07D413/14 , C07D491/20
Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
-
公开(公告)号：US10710980B2
公开(公告)日：2020-07-14
申请号：US16318250
申请日：2017-07-18
Applicant: NOVARTIS AG
Inventor： Luca Arista , Sreehari Babu , Jianwei Bian , Kai Cui , Michael Patrick Dillon , Rene Lattmann , Jialiang Li , Lv Liao , Dimitrios Lizos , Rita Ramos , Nikolaus Johannes Stiefl , Thomas Ullrich , Peggy Usselmann , Xiaoyang Wang , Liladhar Murlidhar Waykole , Sven Weiler , Yubo Zhang , Yizong Zhou , Tingying Zhu
IPC: C07D405/14 , C07D401/14 , C07D401/10 , C07D401/12 , C07D409/14 , C07D213/82 , C07D411/14 , C07D491/107 , A61P19/00 , C07D417/00 , C07D413/00 , C07D419/00 , A61P19/08 , C07D413/10 , C07D413/12 , C07D413/14 , C07D491/20
Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
-
公开(公告)号：US10709712B2
公开(公告)日：2020-07-14
申请号：US16274165
申请日：2019-02-12
Applicant: NOVARTIS AG
Inventor： Robert John Aversa , Paul Andrew Barsanti , Matthew T. Burger , Michael Patrick Dillon , Alan Dipesa , Cheng Hu , Yan Lou , Gisele A. Nishiguchi , Yue Pan , Valery Rostislavovich Polyakov , Savithri Ramurthy , Alice C. Rico , Lina Quattrocchio Setti , Aaron Smith , Sharadha Subramanian , Benjamin R. Taft , Huw Roland Tanner , Lifeng Wan , Naeem Yusuff
IPC: A61K31/5377 , C07D413/04 , A61K31/541 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D403/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D493/10 , C07D403/12 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D401/04 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D491/048 , A61K31/444 , A61K31/501 , C07B59/00 , C07D237/24 , C07D491/04 , C07D491/08
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US09694016B2
公开(公告)日：2017-07-04
申请号：US14774431
申请日：2014-03-13
Applicant: Novartis AG
Inventor： Robert John Aversa , Paul Andrew Barsanti , Matthew Burger , Michael Patrick Dillon , Alan Dipesa , Cheng Hu , Yan Lou , Gisele Nishiguchi , Yue Pan , Valery Polyakov , Savithri Ramurthy , Alice Rico , Lina Setti , Aaron Smith , Sharadha Subramanian , Benjamin Taft , Huw Tanner , Lifeng Wan , Naeem Yusuff
IPC: C07D413/14 , C07D403/14 , C07D403/12 , C07D401/04 , A61K31/5377 , C07D413/04 , A61K31/541 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D403/04 , C07D413/12 , C07D417/12 , C07D493/10 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D491/048
CPC classification number: A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
-
-
-
-
-
Search Results
7
records
(took 0.036 seconds)
